Pricing & Access· July 10, 2026 · 21 min read
AstraZeneca Portfolio Dossier: Farxiga Cliff, Enhertu Pivot, and Soliris Conversion
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Topic
Market Access
Market access strategy, payer engagement, formulary positioning, and commercial launch planning for biopharma products.
Pricing & Access· July 7, 2026 · 17 min read
BMS Portfolio Dossier: The Eliquis Cliff, Opdivo Lifecycle, and Cobenfy Bet
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Specialty· July 7, 2026 · 21 min read
Voranigo (vorasidenib) Glioma Access: Pricing, Biomarker Testing, and Payer PA
By Ran Chen#Oncology#Orphan Drug#Prior Authorization
Evidence· July 4, 2026 · 17 min read
HIV antiretrovirals in FAERS: 205,550 adverse-event reports by the numbers
By Ran Chen#HIV#Real-World Evidence#Label Warnings
Evidence· July 4, 2026 · 16 min read
MS disease-modifying therapies in FAERS: 820,731 adverse-event reports by the numbers
Approvals· July 3, 2026 · 17 min read
Lynavoy (linerixibat) FDA approval: first IBAT inhibitor for PBC pruritus
By Ran Chen#FDA Approval#GI and Liver#Rare Disease
Approvals· July 3, 2026 · 17 min read
Yuviwel (navepegritide) FDA approval and once-weekly achondroplasia access
Pipeline· July 1, 2026 · 19 min read
Centanafadine PDUFA July 24, 2026: Pipeline and Access for Otsuka's NDSRI
By Ran Chen#PDUFA Date#Priority Review#CNS and Migraine
Pricing & Access· June 30, 2026 · 18 min read
China's 2026 Dual-Track Drug Catalog: Reading NHSA Preliminary Numbers
By Ran Chen#China#Market Access#Drug Pricing
Policy· June 30, 2026 · 18 min read
China's 2026 Medical Representative Measures: Building a Compliant Model
By Ran Chen#China#NMPA#Market Access